ANDA 204133, held by Annora Pharma. Pioglitazone Hydrochloride.
As of Nov 21, 2026, ANDA 204133 (Pioglitazone Hydrochloride), held by Annora Pharma, was first approved by FDA on Apr 7, 2014, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 7, 2014 | Original application | Approved | None posted |
| Pioglitazone HydrochlorideEQ 15MG BASE · tablet;oral | Pioglitazone Hydrochloride | Rx |
| Pioglitazone HydrochlorideEQ 30MG BASE · tablet;oral | Pioglitazone Hydrochloride | Rx |
| Pioglitazone HydrochlorideEQ 45MG BASE · tablet;oral | Pioglitazone Hydrochloride | Rx |
| Nov 30, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 30, 2018 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 7, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters